v3.25.1
Stock-based Compensation - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended
Feb. 28, 2025
Mar. 31, 2025
Mar. 31, 2024
Jan. 03, 2025
Jun. 07, 2024
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Common stock shares reserved for issuance   11,854,788      
Share-based compensation expense   $ 2,042,196 $ 53,434    
Employee Stock Option          
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Number of stock options granted   21,329,195 18,039    
Stock option, strike price   $ 2.52 $ 2.55    
Option repriced       $ 1.26  
Stock option, aggregate grant date fair value   $ 43,113,397 $ 34,494    
Performance-based options, Granted   2,056,049      
Performance-based options, weighted average strike price   $ 2.35      
Restricted Stock [Member] | CorHepta Pharmaceuticals [Member]          
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Share-based compensation expense   $ 300,000      
Restricted share issued 1,660,222        
Service based vesting shares 996,133        
Performance based vesting shares 166,023        
Service and performance based vesting shares 498,066        
Fair Value Of Restricted Stock Granted   4,900,000      
Unreognized Compensation Cost   $ 4,600,000      
Two Thousand And Twenty Plan [Member]          
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Number of shares available for grant       31,417,517  
Common stock shares reserved for issuance       2,745,399 2,500,000